Hisamitsu Pharmaceutical Co., Inc. (FRA:HPX)

Germany flag Germany · Delayed Price · Currency is EUR
23.00
+0.20 (0.88%)
Last updated: Dec 5, 2025, 8:03 AM CET
-13.53%
Market Cap 1.62B
Revenue (ttm) 904.68M
Net Income (ttm) 114.51M
Shares Out n/a
EPS (ttm) 1.57
PE Ratio 14.17
Forward PE n/a
Dividend 0.64 (2.75%)
Ex-Dividend Date Aug 28, 2025
Volume n/a
Average Volume n/a
Open 23.00
Previous Close 22.80
Day's Range 23.00 - 23.00
52-Week Range 21.40 - 28.80
Beta n/a
RSI 49.63
Earnings Date Jan 6, 2026

About FRA:HPX

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company offers OTC products, such as, external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. It also exports its products to As... [Read more]

Industry Pharmaceutical Preparations
Founded 1847
Employees 2,799
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol HPX
Full Company Profile

Financial Performance

In 2024, FRA:HPX's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.

Financial numbers in JPY Financial Statements

News

There is no news available yet.